Published in PLoS Med on January 29, 2008
PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS One (2009) 1.52
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol (2009) 1.30
Insidious changes in stromal matrix fuel cancer progression. Mol Cancer Res (2014) 1.09
Low density lipoprotein receptor-related protein 1 (LRP1) forms a signaling complex with platelet-derived growth factor receptor-beta in endosomes and regulates activation of the MAPK pathway. J Biol Chem (2010) 1.00
Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia (2009) 0.99
Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev (2016) 0.91
Platelet-derived growth factor-C (PDGF-C) induces anti-apoptotic effects on macrophages through Akt and Bad phosphorylation. J Biol Chem (2014) 0.86
Platelet-derived growth factors induced lymphangiogenesis: evidence, unanswered questions and upcoming challenges. Arch Med Sci (2015) 0.75
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 8.34
PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol (2005) 4.57
Cervical cancer. Lancet (2003) 4.05
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res (2002) 2.56
Pericytes limit tumor cell metastasis. J Clin Invest (2006) 2.55
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med (2008) 2.40
Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res (2007) 1.83
World Health Organization cancer priorities in developing countries. Ann Oncol (2006) 1.44
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst (2006) 1.39
Platelet-derived growth factor receptor-beta in Gorham's disease. Nat Clin Pract Oncol (2006) 1.23
Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neurooncol (2006) 1.14
New hope for cancer. Time (2001) 0.94
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Photodynamic therapy for cancer. Nat Rev Cancer (2003) 8.00
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med (2009) 5.41
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol (2012) 4.84
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Tissue engineering: creation of long-lasting blood vessels. Nature (2004) 4.50
Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer (2002) 3.96
Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82
Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 3.40
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A (2011) 3.34
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med (2005) 3.19
Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood (2008) 3.13
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol (2009) 3.02
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res (2009) 3.00
Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell (2004) 2.99
Engineering vascularized tissue. Nat Biotechnol (2005) 2.69
Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol (2007) 2.65
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood (2007) 2.64
Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A (2010) 2.62
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A (2012) 2.50
Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res (2006) 2.42
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res (2011) 2.39
The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol (2011) 2.16
In vivo wide-area cellular imaging by side-view endomicroscopy. Nat Methods (2010) 2.10
Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res (2002) 2.09
Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood (2005) 1.98
Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl (2011) 1.93
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Impaired lymphatic contraction associated with immunosuppression. Proc Natl Acad Sci U S A (2011) 1.88
Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks. Nat Methods (2010) 1.88
A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl (2010) 1.84
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther (2008) 1.83
Engineered blood vessel networks connect to host vasculature via wrapping-and-tapping anastomosis. Blood (2011) 1.82
Differential transplantability of tumor-associated stromal cells. Cancer Res (2004) 1.78
Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res (2013) 1.73
Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res (2004) 1.72
A mathematical model of murine metabolic regulation by leptin: energy balance and defense of a stable body weight. Cell Metab (2009) 1.72
Cancer imaging by optical coherence tomography: preclinical progress and clinical potential. Nat Rev Cancer (2012) 1.72
Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem (2001) 1.72
Compact high-quality CdSe-CdS core-shell nanocrystals with narrow emission linewidths and suppressed blinking. Nat Mater (2013) 1.71
Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst (2013) 1.69
NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest (2005) 1.65
Compact biocompatible quantum dots via RAFT-mediated synthesis of imidazole-based random copolymer ligand. J Am Chem Soc (2010) 1.60
Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res (2006) 1.60
Perivascular nitric oxide gradients normalize tumor vasculature. Nat Med (2008) 1.56
Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci U S A (2011) 1.54
VEGFR1-activity-independent metastasis formation. Nature (2009) 1.47
Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys J (2010) 1.47
Targeted induction of lung endothelial cell apoptosis causes emphysema-like changes in the mouse. J Biol Chem (2008) 1.44
Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med (2004) 1.42
Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. Proc Natl Acad Sci U S A (2013) 1.41
Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res (2003) 1.40
InAs(ZnCdS) quantum dots optimized for biological imaging in the near-infrared. J Am Chem Soc (2010) 1.39
Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS One (2009) 1.37
C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc Natl Acad Sci U S A (2010) 1.30
Endothelial nitric oxide synthase regulates microlymphatic flow via collecting lymphatics. Circ Res (2004) 1.30
Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res (2002) 1.29
Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res (2006) 1.28
Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell (2004) 1.28
Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proc Natl Acad Sci U S A (2011) 1.27
Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells. PLoS One (2009) 1.25
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res (2010) 1.24
VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. PLoS One (2009) 1.23
Benefits of vascular normalization are dose and time dependent--letter. Cancer Res (2013) 1.22
Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Clin Cancer Res (2004) 1.17
Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res (2006) 1.17
Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res (2010) 1.17
Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res (2003) 1.14
In vivo imaging of tumors. Cold Spring Harb Protoc (2010) 1.13
Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res (2009) 1.13
Influence of tumor cell and stroma sensitivity on tumor response to radiation. Cancer Res (2007) 1.09
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci U S A (2012) 1.09
Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice. Comp Med (2008) 1.07
PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res (2011) 1.07
Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal (2013) 1.07
Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast. Opt Lett (2009) 1.07
Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Res (2002) 1.05
Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts. Cancer Res (2003) 1.04
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One (2012) 1.03
A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11. PLoS One (2008) 0.96
Normalization of the tumor vasculature through oncogenic inhibition: an emerging paradigm in tumor biology. Proc Natl Acad Sci U S A (2012) 0.96
Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels in vivo. Am J Pathol (2009) 0.95
Cationic nanoparticles have superior transvascular flux into solid tumors: insights from a mathematical model. Ann Biomed Eng (2012) 0.95
A transient parabiosis skin transplantation model in mice. Nat Protoc (2012) 0.94
Video-rate resonant scanning multiphoton microscopy: An emerging technique for intravital imaging of the tumor microenvironment. Intravital (2012) 0.93
Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. Cancer Res (2002) 0.92
Molecular regulation of microlymphatic formation and function: role of nitric oxide. Trends Cardiovasc Med (2005) 0.89
From the Guest Editors: Role of Tumor Microenvironment in Tumor Progression and Treatment Response: A 30 Years' Journey. Cancer J (2015) 0.88
Green fluorescent protein (GFP)-expressing tumor model derived from a spontaneous osteosarcoma in a vascular endothelial growth factor (VEGF)-GFP transgenic mouse. Comp Med (2005) 0.87
Spontaneous nonthymic tumors in SCID mice. Comp Med (2011) 0.87
Evolution of oxygen and glucose concentration profiles in a tissue-mimetic culture system of embryonic stem cells. Ann Biomed Eng (2006) 0.87
Development of a ligand-directed approach to study the pathogenesis of invasive aspergillosis. Infect Immun (2005) 0.86
Small blood vessel engineering. Methods Mol Med (2007) 0.86
Transgenic mice for cGMP imaging. Circ Res (2013) 0.86
The original Pathologische Anatomie Leiden-Endothelium monoclonal antibody recognizes a vascular endothelial growth factor binding site within neuropilin-1. Cancer Res (2007) 0.84
Spatial charge configuration regulates nanoparticle transport and binding behavior in vivo. Angew Chem Int Ed Engl (2012) 0.84